{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T05:04:14Z","timestamp":1782795854633,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,11]],"date-time":"2018-11-11T00:00:00Z","timestamp":1541894400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","award":["AP-CL-ALOP-PI-005776"],"award-info":[{"award-number":["AP-CL-ALOP-PI-005776"]}],"id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s00403-018-1876-y","type":"journal-article","created":{"date-parts":[[2018,11,11]],"date-time":"2018-11-11T00:58:49Z","timestamp":1541897929000},"page":"29-36","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata"],"prefix":"10.1007","volume":"311","author":[{"given":"Daniela","family":"Mikhaylov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Pavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Kimmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Nia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hashim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali S.","family":"Vekaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Taliercio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giselle","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Karalekas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Baum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasaman","family":"Mansouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Guttman-Yassky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,11]]},"reference":[{"key":"1876_CR1","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3109\/15569527.2013.839997","volume":"33","author":"G Acikgoz","year":"2014","unstructured":"Acikgoz G, Caliskan E, Tunca M, Yeniay Y, Akar A (2014) The effect of oral cyclosporine in the treatment of severe alopecia areata. Cutan Ocul Toxicol 33:247\u2013252. \n                    https:\/\/doi.org\/10.3109\/15569527.2013.839997","journal-title":"Cutan Ocul Toxicol"},{"key":"1876_CR2","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jaad.2009.10.031","volume":"62","author":"A Alkhalifah","year":"2010","unstructured":"Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J (2010) Alopecia areata update: part II. Treatment. J Am Acad Dermatol 62:191\u2013202. \n                    https:\/\/doi.org\/10.1016\/j.jaad.2009.10.031\n                    \n                   quiz 203 \u2013 194.","journal-title":"J Am Acad Dermatol"},{"key":"1876_CR3","doi-asserted-by":"publisher","first-page":"122","DOI":"10.4103\/2229-5178.131076","volume":"5","author":"OA Bakry","year":"2014","unstructured":"Bakry OA, El Shazly RM, Basha MA, Mostafa H (2014) Total serum immunoglobulin E in patients with alopecia areata. Indian dermatology online journal 5:122\u2013127. \n                    https:\/\/doi.org\/10.4103\/2229-5178.131076","journal-title":"Indian dermatology online journal"},{"key":"1876_CR4","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jaad.2017.03.024","volume":"77","author":"CB Bayart","year":"2017","unstructured":"Bayart CB, DeNiro KL, Brichta L, Craiglow BG, Sidbury R (2017) Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata. J Am Acad Dermatol 77:167\u2013170. \n                    https:\/\/doi.org\/10.1016\/j.jaad.2017.03.024","journal-title":"J Am Acad Dermatol"},{"key":"1876_CR5","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaad.2014.04.036","volume":"71","author":"K Chiang","year":"2014","unstructured":"Chiang K, Atanaskova Mesinkovska N, Amoretti A, Piliang MP, Kyei A, Bergfeld WF (2014) Clinical efficacy of diphenylcyclopropenone in alopecia areata: retrospective data analysis of 50 patients. J Am Acad Dermatol 71:595\u2013597. \n                    https:\/\/doi.org\/10.1016\/j.jaad.2014.04.036","journal-title":"J Am Acad Dermatol"},{"key":"1876_CR6","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1038\/jid.2014.260","volume":"134","author":"BG Craiglow","year":"2014","unstructured":"Craiglow BG, King BA (2014) Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Investig Dermatol 134:2988\u20132990. \n                    https:\/\/doi.org\/10.1038\/jid.2014.260","journal-title":"J Investig Dermatol"},{"key":"1876_CR7","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/all.13346","volume":"73","author":"T Czarnowicki","year":"2018","unstructured":"Czarnowicki T, He HY, Wen HC, Hashim PW, Nia JK, Malik K, Estrada Y, Kimmel GW, Taliercio M, Krueger JG, Guttman-Yassky E (2018) Alopecia areata is characterized by expansion of circulating Th2\/Tc2\/Th22, within the skin-homing and systemic T-cell populations. Allergy 73:713\u2013723. \n                    https:\/\/doi.org\/10.1111\/all.13346","journal-title":"Allergy"},{"key":"1876_CR8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.4103\/0974-7753.136748","volume":"6","author":"TR Hollanda de","year":"2014","unstructured":"de Hollanda TR, Sodre CT, Brasil MA, Ramos ESM (2014) Quality of life in alopecia areata: a case-control study. Int J Trichol 6:8\u201312. \n                    https:\/\/doi.org\/10.4103\/0974-7753.136748","journal-title":"Int J Trichol"},{"key":"1876_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004413.pub2","author":"FM Delamere","year":"2008","unstructured":"Delamere FM, Sladden MM, Dobbins HM, Leonardi-Bee J (2008) Interventions for alopecia areata. Cochrane Database Syst Rev Cd004413. \n                    https:\/\/doi.org\/10.1002\/14651858.CD004413.pub2","journal-title":"Cochrane Database Syst Rev Cd004413"},{"key":"1876_CR10","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1136\/annrheumdis-2015-207963","volume":"75","author":"CJ Edwards","year":"2016","unstructured":"Edwards CJ, Blanco FJ, Crowley J, Birbara CA, Jaworski J, Aelion J, Stevens RM, Vessey A, Zhan X, Bird P (2016) Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis 75:1065\u20131073. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2015-207963","journal-title":"Ann Rheum Dis"},{"key":"1876_CR11","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/j.1365-4632.2010.04576.x","volume":"49","author":"S Farshi","year":"2010","unstructured":"Farshi S, Mansouri P, Safar F, Khiabanloo SR (2010) Could azathioprine be considered as a therapeutic alternative in the treatment of alopecia areata? A pilot study. Int J Dermatol 49:1188\u20131193. \n                    https:\/\/doi.org\/10.1111\/j.1365-4632.2010.04576.x","journal-title":"Int J Dermatol"},{"key":"1876_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-018-0511-8","author":"VKV Gade","year":"2018","unstructured":"Gade VKV, Mony A, Munisamy M, Chandrashekar L, Rajappa M (2018) An investigation of vitamin D status in alopecia areata. Clin Exp Med. \n                    https:\/\/doi.org\/10.1007\/s10238-018-0511-8","journal-title":"Clin Exp Med"},{"key":"1876_CR13","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.autrev.2005.07.001","volume":"5","author":"A Gilhar","year":"2006","unstructured":"Gilhar A, Kalish RS (2006) Alopecia areata: a tissue specific autoimmune disease of the hair follicle. Autoimmun Rev 5:64\u201369. \n                    https:\/\/doi.org\/10.1016\/j.autrev.2005.07.001","journal-title":"Autoimmun Rev"},{"key":"1876_CR14","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1684\/ejd.2013.2042","volume":"23","author":"CN Giordano","year":"2013","unstructured":"Giordano CN, Sinha AA (2013) Cytokine pathways and interactions in alopecia areata. Eur J Dermatol EJD 23:308\u2013318. \n                    https:\/\/doi.org\/10.1684\/ejd.2013.2042","journal-title":"Eur J Dermatol EJD"},{"key":"1876_CR15","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jaci.2015.11.001","volume":"137","author":"E Guttman-Yassky","year":"2016","unstructured":"Guttman-Yassky E, Ungar B, Noda S, Suprun M, Shroff A, Dutt R, Khattri S, Min M, Mansouri Y, Zheng X, Estrada YD, Singer GK, Suarez-Farinas M, Krueger JG, Lebwohl MG (2016) Extensive alopecia areata is reversed by IL-12\/IL-23p40 cytokine antagonism. J Allergy Clin Immunol 137:301\u2013304. \n                    https:\/\/doi.org\/10.1016\/j.jaci.2015.11.001","journal-title":"J Allergy Clin Immunol"},{"key":"1876_CR16","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/jidsymp.2015.41","volume":"17","author":"MK Hordinsky","year":"2015","unstructured":"Hordinsky MK (2015) Current treatments for alopecia areata. J Investig Dermatol Symp Proc 17:44\u201346. \n                    https:\/\/doi.org\/10.1038\/jidsymp.2015.41","journal-title":"J Investig Dermatol Symp Proc"},{"key":"1876_CR17","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/jamadermatol.2013.3049","volume":"149","author":"KP Huang","year":"2013","unstructured":"Huang KP, Mullangi S, Guo Y, Qureshi AA (2013) Autoimmune, atopic, and mental health comorbid conditions associated with alopecia areata in the United States. JAMA Dermatol 149:789\u2013794. \n                    https:\/\/doi.org\/10.1001\/jamadermatol.2013.3049","journal-title":"JAMA Dermatol"},{"key":"1876_CR18","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ebiom.2015.02.015","volume":"2","author":"A Jabbari","year":"2015","unstructured":"Jabbari A, Dai Z, Xing L, Cerise JE, Ramot Y, Berkun Y, Sanchez GA, Goldbach-Mansky R, Christiano AM, Clynes R, Zlotogorski A (2015) Reversal of alopecia areata following treatment with the JAK1\/2 inhibitor baricitinib. EBioMedicine 2:351\u2013355. \n                    https:\/\/doi.org\/10.1016\/j.ebiom.2015.02.015","journal-title":"EBioMedicine"},{"key":"1876_CR19","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jdermsci.2014.11.009","volume":"77","author":"A Keren","year":"2015","unstructured":"Keren A, Shemer A, Ullmann Y, Paus R, Gilhar A (2015) The PDE4 inhibitor, apremilast, suppresses experimentally induced alopecia areata in human skin in vivo. J Dermatol Sci 77:74\u201376. \n                    https:\/\/doi.org\/10.1016\/j.jdermsci.2014.11.009","journal-title":"J Dermatol Sci"},{"key":"1876_CR20","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1159\/000092287","volume":"212","author":"M Kurosawa","year":"2006","unstructured":"Kurosawa M, Nakagawa S, Mizuashi M, Sasaki Y, Kawamura M, Saito M, Aiba S (2006) A comparison of the efficacy, relapse rate and side effects among three modalities of systemic corticosteroid therapy for alopecia areata. Dermatology 212:361\u2013365. \n                    https:\/\/doi.org\/10.1159\/000092287","journal-title":"Dermatology"},{"key":"1876_CR21","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1177\/1203475417748886","volume":"22","author":"A Langley","year":"2018","unstructured":"Langley A, Beecker J (2018) Management of common side effects of apremilast. J Cutan Med Surg 22:415\u2013421. \n                    https:\/\/doi.org\/10.1177\/1203475417748886","journal-title":"J Cutan Med Surg"},{"key":"1876_CR22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jaad.2016.09.007","volume":"76","author":"LY Liu","year":"2017","unstructured":"Liu LY, Craiglow BG, Dai F, King BA (2017) Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients. J Am Acad Dermatol 76:22\u201328. \n                    https:\/\/doi.org\/10.1016\/j.jaad.2016.09.007","journal-title":"J Am Acad Dermatol"},{"key":"1876_CR23","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.jaad.2017.05.034","volume":"77","author":"LY Liu","year":"2017","unstructured":"Liu LY, King BA (2017) Lack of efficacy of apremilast in 9 patients with severe alopecia areata. J Am Acad Dermatol 77:773\u2013774. \n                    https:\/\/doi.org\/10.1016\/j.jaad.2017.05.034","journal-title":"J Am Acad Dermatol"},{"key":"1876_CR24","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1046\/j.1365-2133.2003.05535.x","volume":"149","author":"SP MacDonald Hull","year":"2003","unstructured":"MacDonald Hull SP, Wood ML, Hutchinson PE, Sladden M, Messenger AG (2003) Guidelines for the management of alopecia areata. Br J Dermatol 149:692\u2013699","journal-title":"Br J Dermatol"},{"key":"1876_CR25","doi-asserted-by":"publisher","first-page":"e89790","DOI":"10.1172\/jci.insight.89790","volume":"1","author":"J Mackay-Wiggan","year":"2016","unstructured":"Mackay-Wiggan J, Jabbari A, Nguyen N, Cerise JE, Clark C, Ulerio G, Furniss M, Vaughan R, Christiano AM, Clynes R (2016) Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI Insight 1:e89790. \n                    https:\/\/doi.org\/10.1172\/jci.insight.89790","journal-title":"JCI Insight"},{"key":"1876_CR26","doi-asserted-by":"publisher","first-page":"ii111","DOI":"10.1136\/annrheumdis-2012-202576","volume":"72","author":"JJ O\u2019Shea","year":"2013","unstructured":"O\u2019Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A (2013) Janus kinase Inhibitors in autoimmune diseases. Ann Rheum Dis 72:ii111\u2013ii115. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2012-202576","journal-title":"Ann Rheum Dis"},{"key":"1876_CR27","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/j.1529-8019.2011.01420.x","volume":"24","author":"N Otberg","year":"2011","unstructured":"Otberg N (2011) Systemic treatment for alopecia areata. Dermatol Ther 24:320\u2013325. \n                    https:\/\/doi.org\/10.1111\/j.1529-8019.2011.01420.x","journal-title":"Dermatol Ther"},{"key":"1876_CR28","doi-asserted-by":"publisher","first-page":"12","DOI":"10.5021\/ad.2013.25.1.12","volume":"25","author":"KY Park","year":"2013","unstructured":"Park KY, Jang WS, Son IP, Choi SY, Lee MY, Kim BJ, Kim MN, Ro BI (2013) Combination therapy with cyclosporine and psoralen plus ultraviolet a in the patients with severe alopecia areata: a retrospective study with a self-controlled design. Ann Dermatol 25:12\u201316. \n                    https:\/\/doi.org\/10.5021\/ad.2013.25.1.12","journal-title":"Ann Dermatol"},{"key":"1876_CR29","first-page":"835","volume":"17","author":"C Pincelli","year":"2018","unstructured":"Pincelli C, Schafer PH, French LE, Augustin M, Krueger JG (2018) Mechanisms underlying the clinical effects of apremilast for psoriasis. J Drugs Dermatol JDD 17:835\u2013840","journal-title":"J Drugs Dermatol JDD"},{"key":"1876_CR30","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1080\/14712598.2016.1188076","volume":"16","author":"Y Renert-Yuval","year":"2016","unstructured":"Renert-Yuval Y, Guttman-Yassky E (2016) A novel therapeutic paradigm for patients with extensive alopecia areata. Expert Opin Biol Ther 16:1005\u20131014. \n                    https:\/\/doi.org\/10.1080\/14712598.2016.1188076","journal-title":"Expert Opin Biol Ther"},{"key":"1876_CR31","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1007\/s12325-017-0542-7","volume":"34","author":"Y Renert-Yuval","year":"2017","unstructured":"Renert-Yuval Y, Guttman-Yassky E (2017) The changing landscape of alopecia areata: the therapeutic paradigm. Adv Ther 34:1594\u20131609. \n                    https:\/\/doi.org\/10.1007\/s12325-017-0542-7","journal-title":"Adv Ther"},{"key":"1876_CR32","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1001\/archdermatol.2012.812","volume":"148","author":"A Samrao","year":"2012","unstructured":"Samrao A, Berry TM, Goreshi R, Simpson EL (2012) A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults. Arch Dermatol 148:890\u2013897. \n                    https:\/\/doi.org\/10.1001\/archdermatol.2012.812","journal-title":"Arch Dermatol"},{"key":"1876_CR33","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1016\/j.bcp.2012.01.001","volume":"83","author":"P Schafer","year":"2012","unstructured":"Schafer P (2012) Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol 83:1583\u20131590. \n                    https:\/\/doi.org\/10.1016\/j.bcp.2012.01.001","journal-title":"Biochem Pharmacol"},{"key":"1876_CR34","doi-asserted-by":"publisher","first-page":"750","DOI":"10.7326\/L16-0125","volume":"165","author":"M Scheinberg","year":"2016","unstructured":"Scheinberg M, Ferreira S (2016) Reversal of alopecia universalis by tofacitinib: a case report. Ann Intern Med 165:750\u2013751. \n                    https:\/\/doi.org\/10.7326\/L16-0125","journal-title":"Ann Intern Med"},{"key":"1876_CR35","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.jaci.2015.06.032","volume":"136","author":"M Suarez-Farinas","year":"2015","unstructured":"Suarez-Farinas M, Ungar B, Noda S, Shroff A, Mansouri Y, Fuentes-Duculan J, Czernik A, Zheng X, Estrada YD, Xu H, Peng X, Shemer A, Krueger JG, Lebwohl MG, Guttman-Yassky E (2015) Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17\/TH22 skewing. J Allergy Clin Immunol 136:1277\u20131287. \n                    https:\/\/doi.org\/10.1016\/j.jaci.2015.06.032","journal-title":"J Allergy Clin Immunol"},{"key":"1876_CR36","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/bjd.12396","volume":"169","author":"MK Tembhre","year":"2013","unstructured":"Tembhre MK, Sharma VK (2013) T-helper and regulatory T-cell cytokines in the peripheral blood of patients with active alopecia areata. Br J Dermatol 169:543\u2013548. \n                    https:\/\/doi.org\/10.1111\/bjd.12396","journal-title":"Br J Dermatol"},{"key":"1876_CR37","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jaad.2006.05.008","volume":"55","author":"A Tosti","year":"2006","unstructured":"Tosti A, Bellavista S, Iorizzo M (2006) Alopecia areata: a long term follow-up study of 191 patients. J Am Acad Dermatol 55:438\u2013441. \n                    https:\/\/doi.org\/10.1016\/j.jaad.2006.05.008","journal-title":"J Am Acad Dermatol"},{"key":"1876_CR38","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1038\/jidsymp.2013.8","volume":"16","author":"TA Waldmann","year":"2013","unstructured":"Waldmann TA (2013) The biology of IL-15: implications for cancer therapy and the treatment of autoimmune disorders. J Investig Dermatol Symp Proc 16:S28\u2013S30. \n                    https:\/\/doi.org\/10.1038\/jidsymp.2013.8","journal-title":"J Investig Dermatol Symp Proc"},{"key":"1876_CR39","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1007\/s12325-017-0540-9","volume":"34","author":"ECE Wang","year":"2017","unstructured":"Wang ECE, Christiano AM (2017) The changing landscape of alopecia areata: the translational landscape. Adv Ther 34:1586\u20131593. \n                    https:\/\/doi.org\/10.1007\/s12325-017-0540-9","journal-title":"Adv Ther"},{"key":"1876_CR40","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/nm.3645","volume":"20","author":"L Xing","year":"2014","unstructured":"Xing L, Dai Z, Jabbari A, Cerise JE, Higgins CA, Gong W, de Jong A, Harel S, DeStefano GM, Rothman L, Singh P, Petukhova L, Mackay-Wiggan J, Christiano AM, Clynes R (2014) Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med 20:1043\u20131049. \n                    https:\/\/doi.org\/10.1038\/nm.3645","journal-title":"Nat Med"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00403-018-1876-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-018-1876-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-018-1876-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,10]],"date-time":"2019-11-10T19:11:49Z","timestamp":1573413109000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00403-018-1876-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,11]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["1876"],"URL":"https:\/\/doi.org\/10.1007\/s00403-018-1876-y","relation":{},"ISSN":["0340-3696","1432-069X"],"issn-type":[{"value":"0340-3696","type":"print"},{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,11]]},"assertion":[{"value":"20 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Daniela Mikhaylov, Ana Pavel, Christopher Yao, Giselle Singer, Mark Taliercio, Rachel Karalekas, John Nia, Peter Hashim, Grace Kimmel, Danielle Baum, Yasaman Mansouri, and Anjali S. Vekaria have no conflicts of interest to disclose. Dr. Emma Guttman-Yassky is a board member of Sanofi Aventis, Regeneron, Stiefel\/GlaxoSmithKline, MedImmune, Celgene, Anacor, AnaptysBio, Celsus, Dermira, Galderma, Glenmark, Novartis, Pfizer, Vitae and Leo Pharma; has received consultancy fees from Regeneron, Sanofi, MedImmune, Celgene, Stiefel\/GlaxoSmithKline, Celsus, BMS, Amgen, Drais, AbbVie, Anacor, AnaptysBio, Dermira, Galderma, Glenmark, LEO Pharma, Novartis, Pfizer, Vitae, Mitsubishi Tanabe and Eli Lilly; and has received research support from Janssen, Regeneron, Celgene, BMS, Novartis, Merck, LEO Pharma and Dermira. Dr. Mark Lebwohl is an employee of Mount Sinai, which receives research funds from Amgen, Anacor Pharmaceuticals Inc, Boehringer Ingelheim, Celgene, Eli Lilly and Company, Janssen Biotech, Kadmon Corporation, LEO Pharmaceuticals, MedImmune, Novartis Pharmaceuticals Corporation, Pfizer, Sun Pharmaceuticals Industries Ltd, and Valeant Pharmaceuticals. The authors did not receive any form of compensation, either directly or indirectly, from any company or agency related to the development, authorship, or publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}